The global generative AI in healthcare market size accounted for USD 1.95 billion in 2024, grew to USD 2.64 billion in 2025 and is expected to be worth around USD 39.70 billion by 2034, registering a CAGR of 35.17% between 2024 and 2034. The North America generative AI in healthcare market size is calculated at USD 720 million in 2024 and is estimated to grow at a CAGR of 35.35% during the forecast period.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Generative AI in Healthcare Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Generative AI in Healthcare Market, by Application, 2024-2034
8.1.1 Clinical
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. System
8.1.2.1. Market Revenue and Forecast (2021-2034)
9.1. Generative AI in Healthcare Market, by Function, 2024-2034
9.1.1. AI-Assisted Robotic Surgery
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Virtual Nursing Assistants
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Aid Clinical Judgment/Diagnosis
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Workflow & Administrative Tasks
9.1.4.1. Market Revenue and Forecast (2021-2034)
9.1.5. Image Analysis
9.1.5.1. Market Revenue and Forecast (2021-2034)
10.1. Generative AI in Healthcare Market, by End User, 2024-2034
10.1.1. Hospitals & Clinics
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Clinical Research
10.1.2.1. Market Revenue and Forecast (2021-2034)
10.1.3. Healthcare Organizations
10.1.3.1. Market Revenue and Forecast (2021-2034)
10.1.4. Diagnostic Centers
10.1.4.1. Market Revenue and Forecast (2021-2034)
10.1.5. Others
10.1.5.1. Market Revenue and Forecast (2021-2034)
11.1. North America
11.1.1. Market Revenue and Forecast, by Application (2021-2034)
11.1.2. Market Revenue and Forecast, by Function (2021-2034)
11.1.3. Market Revenue and Forecast, by End User (2021-2034)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Application (2021-2034)
11.1.4.2. Market Revenue and Forecast, by Function (2021-2034)
11.1.4.3. Market Revenue and Forecast, by End User (2021-2034)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Application (2021-2034)
11.1.5.2. Market Revenue and Forecast, by Function (2021-2034)
11.1.5.3. Market Revenue and Forecast, by End User (2021-2034)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Application (2021-2034)
11.2.2. Market Revenue and Forecast, by Function (2021-2034)
11.2.3. Market Revenue and Forecast, by End User (2021-2034)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Application (2021-2034)
11.2.4.2. Market Revenue and Forecast, by Function (2021-2034)
11.2.4.3. Market Revenue and Forecast, by End User (2021-2034)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Application (2021-2034)
11.2.5.2. Market Revenue and Forecast, by Function (2021-2034)
11.2.5.3. Market Revenue and Forecast, by End User (2021-2034)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Application (2021-2034)
11.2.6.2. Market Revenue and Forecast, by Function (2021-2034)
11.2.6.3. Market Revenue and Forecast, by End User (2021-2034)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Application (2021-2034)
11.2.7.2. Market Revenue and Forecast, by Function (2021-2034)
11.2.7.3. Market Revenue and Forecast, by End User (2021-2034)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Application (2021-2034)
11.3.2. Market Revenue and Forecast, by Function (2021-2034)
11.3.3. Market Revenue and Forecast, by End User (2021-2034)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Application (2021-2034)
11.3.4.2. Market Revenue and Forecast, by Function (2021-2034)
11.3.4.3. Market Revenue and Forecast, by End User (2021-2034)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Application (2021-2034)
11.3.5.2. Market Revenue and Forecast, by Function (2021-2034)
11.3.5.3. Market Revenue and Forecast, by End User (2021-2034)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Application (2021-2034)
11.3.6.2. Market Revenue and Forecast, by Function (2021-2034)
11.3.6.3. Market Revenue and Forecast, by End User (2021-2034)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Application (2021-2034)
11.3.7.2. Market Revenue and Forecast, by Function (2021-2034)
11.3.7.3. Market Revenue and Forecast, by End User (2021-2034)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Application (2021-2034)
11.4.2. Market Revenue and Forecast, by Function (2021-2034)
11.4.3. Market Revenue and Forecast, by End User (2021-2034)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Application (2021-2034)
11.4.4.2. Market Revenue and Forecast, by Function (2021-2034)
11.4.4.3. Market Revenue and Forecast, by End User (2021-2034)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Application (2021-2034)
11.4.5.2. Market Revenue and Forecast, by Function (2021-2034)
11.4.5.3. Market Revenue and Forecast, by End User (2021-2034)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Application (2021-2034)
11.4.6.2. Market Revenue and Forecast, by Function (2021-2034)
11.4.6.3. Market Revenue and Forecast, by End User (2021-2034)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Application (2021-2034)
11.4.7.2. Market Revenue and Forecast, by Function (2021-2034)
11.4.7.3. Market Revenue and Forecast, by End User (2021-2034)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Application (2021-2034)
11.5.2. Market Revenue and Forecast, by Function (2021-2034)
11.5.3. Market Revenue and Forecast, by End User (2021-2034)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Application (2021-2034)
11.5.4.2. Market Revenue and Forecast, by Function (2021-2034)
11.5.4.3. Market Revenue and Forecast, by End User (2021-2034)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Application (2021-2034)
11.5.5.2. Market Revenue and Forecast, by Function (2021-2034)
11.5.5.3. Market Revenue and Forecast, by End User (2021-2034)
12.1. Syntegra
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. NioyaTech
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Saxon
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. IBM Watson
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Microsoft Corporation
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Google LLC
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Tencent Holdings Ltd.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Neuralink Corporation
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Johnson & Johnson
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. OpenAI
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client